secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kyverna Therapeutics, Inc. (KYTX)
CIK:        0001994702
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0000950170-25-007220
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kyverna appoints Naji Gehchan as Chief Medical and Development Officer; grants 425,000 option shares
--------------------------------------------------------------------------------

- Naji Gehchan, MD/MBA, joins as Chief Medical and Development Officer; led clinical development at Eli Lilly including imlunestrant.
- Inducement grant of options for 425,000 shares under 2024 Inducement Equity Plan; exercise price at Jan 22 closing price.
- Options vest over 4 years (25% at 1-year anniversary, remainder monthly thereafter) contingent on continued service.
- Dominic Borie, former President of R&D, transitions to Strategic Advisor to the CEO and Board.
- Gehchan brings 20+ years experience in immunology and late-stage development for Kyverna's KYV-101 CAR-T program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025007220/0000950170-25-007220-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1994702/000095017025007220/kytx-20250121.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-007220

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer